Noh J, Choi WS, Noh G, et al. .Presence of Foxp3-expressing CD19+CD5+ B Cells in Human Peripheral Blood Mononuclear Cells: Human CD19+CD5+Foxp3+ Regulatory B Cell (Breg) [J].Immune Netw,2010,10(6):247-249.
[2]
Dudley A, Thomason J, Fritz S, et al. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin[J]. J Vet Intern Med, 2013;27(1):141-149.
[3]
Ahmad E,?Elgohary T,?Ibrahim H. Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia[J]. J Investig Allergol Clin Immunol,2011,21(4):297-304.
[4]
Chorzempa A, Tamis J, Simon C,et al. Safety and feasibility of intra-arterial bivalirudin bolus administration during primary angioplasty[J]. Coron Artery Dis, 2013,;24(5):419-421.
[5]
de Vries JI, van Pampus MG, Hague WM et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT[J]. J Thromb Haemost, 2012,;10(1):64-72.
[6]
Voora D, Horton J, Shah SH, et al. Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use[J]. Am Heart J, 2011,162(1):166-172.e1.
[7]
Hoyer KK,?Kuswant WF,?Gallo E,?et al.Distinct roles of helper?T-cell?subsets in a systemic autoimmune disease[J]. Blood,2009,113(2):389-395.
[8]
Blann AD, Kuzniatsova N, Velu S, et al. Renal function and aspirin resistance in patients with coronary artery disease[J]. Thromb Res, 2012,130(3):e103-106.
[9]
Sindhava VJ, Bondada S. Multiple regulatory mechanisms control B-1 B?cell?activation[J]. Front Immunol,2012,3:372.
[10]
Grosser T, Fries S, Lawson JA et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin[J]. Circulation, 2013,127(3):377-385.
[11]
Fukuyama T, Kosaka T, Miyashita L，et al. Role of regulatory T cells in the induction of atopic dermatitis by immunosuppressive chemicals[J]. Toxicol Lett,2012,18;213(3):392-401.
[12]
Fukutomi Y, Taniguchi M, Tsuburai T, et al. Obesity and aspirin intolerance are risk factors for difficult-to-treat asthma in Japanese non-atopic women[J]. Clin Exp Allergy, 2012,42(5):738-746.
[13]
Vadasz Z, Haj T, Kessel A, et al. B-regulatory cells in autoimmunity and immune mediated inflammation[J]. FEBS Lett,2013,587(13):2074-2078.
[14]
Kim KE, Woo KS, Goh RY, et al. Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients[J]. Int J Lab Hematol, 2010,32(1 Pt 2):50-55.
[15]
Kaushal M, Sen R. Posterior endoscopic discectomy: Results in 300 patients[J]. Indian J Orthop, 2012,46(1):81-85.
[16]
Berent R, Sinzinger H. "Aspirin - resistance"? A few critical considerations on definition, terminology, diagnosis, clinical value, natural course of atherosclerotic disease, and therapeutic consequences[J]. Vasa, 2011,40(6):429-438.
[17]
Al-Azzam SI, Alzoubi KH, Khabour OF et al. Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach[J]. Int J Clin Pharmacol Ther, 2013,51(3):179-186.
[18]
Maseda D, Candando KM, Smith SH, et al.Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice[J]. J Immunol,2013,191(5):2780-2795.
[19]
Carroll RC, Craft RM, Snider CC, et al. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane[J]. Anesth Analg, 2013,116(2):282-286.
[20]
Kasmeridis C, Apostolakis S, Lip GY. Aspirin and aspirin resistance in coronary artery disease[J]. Curr Opin Pharmacol, 2013,13(2):242-250.
[21]
Vadasz D, Sztriha LK, Sas K, et al. Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part I: Concept of resistance[J]. Ideggyogy Sz, 2012,65(11-12):377-385.
[22]
Tantry US, Gurbel PA. Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring[J]. Curr Pharm Des, 2013,19(21):3795-3815.
